Browse News
Filter News
Found 51 articles
-
Priothera cleared to begin Japanese arm of pivotal Phase 3 study with mocravimod in patients with Acute Myeloid Leukemia undergoing allogeneic Hematopoietic Cell Transplant
2/27/2023
Priothera announced that it received clearance from the Pharmaceuticals and Medical Devices Agency in Japan for the pivotal global MO-TRANS Phase 3 study evaluating mocravimod in Acute Myeloid Leukemia patients undergoing allogeneic hematopoietic cell transplant.
-
Shionogi Presents Pivotal Ensitrelvir Fumaric Acid Phase 3 Data and Exploratory Long COVID Data at CROI
2/21/2023
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") today, at the 30th Conference on Retroviruses and Opportunistic Infections (CROI), presented further results from the Phase 3 part of the pivotal SCORPIO-SR trial.
-
Shionogi Advances Ensitrelvir Fumaric Acid COVID-19 Antiviral Clinical Program
2/15/2023
Shionogi & Co., Ltd. announced progress on its comprehensive clinical development program for the novel COVID-19 oral antiviral ensitrelvir.
-
Artificial Tendons and Ligaments Market is Expected To Reach USD 60.90 Billion By 2028 - Reports and Data
9/8/2022
According to the current analysis of Reports and Data, the global artificial tendons and ligaments market was valued at USD 23.16 Billion in 2020 and is expected to reach USD 60.90 Billion by the year 2028, at a CAGR of 13.2%
-
Researchers at Hokkaido University in Japan, in a collaboration with American scientists, may have unlocked the mechanism that drives widespread inflammation in inflammatory diseases.
-
New Data for Shionogi’s COVID-19 Once-Daily Oral Antiviral S-217622 Show Rapid Virus Clearance
4/23/2022
Shionogi & Co., Ltd. announced new results from two late-breaking presentations of S-217622 at the 32nd European Congress of Clinical Microbiology & Infectious Diseases in Lisbon, 23 – 26 April.
-
Shionogi Presents the Results of COVID-19 Therapeutic Agent at ISIRV-WHO Virtual Conference
10/21/2021
Shionogi Presents the Results of COVID-19 Therapeutic Agent at ISIRV-WHO Virtual Conference
-
Asensus Surgical, Inc. Announces Sapporo Medical University Hospital in Japan to Initiate Senhance Robotic Surgery Program
9/29/2021
Asensus Surgical, Inc. today announced Sapporo Medical University Hospital, located in Hokkaido, Japan, has entered into an agreement to lease and utilize a Senhance® Surgical System.
-
Just as it was beginning to appear safe to return to maskless, pre-pandemic life, the Delta variant of the SARS-CoV-2 virus emerged. It is fast-spreading, more likely to lead to hospitalizations, and accounts for most of the breakout infections among fully vaccinated individuals.
-
SanBio Announces Publication of STEMTRA Phase 2 Interim Analysis for SB623 in Neurology
1/5/2021
SanBio Announces Publication of STEMTRA Phase 2 Interim Analysis for SB623 in Neurology Publication Affirms SanBio’s Approach to Treating Chronic Traumatic Brain Injury Patients
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
Eisai: Industry-Academia-Government Joint Development Agreement Aiming for Drug Discovery for Systemic Lupus Erythematosus by Practical Application of Toll-Like Receptor Research Concluded
7/13/2020
Eisai Company, Ltd. announced today that it has entered into an industry-academia-government joint research agreement with four universities in Japan concerning the "Industrialization of Japan-originated Toll-like receptor research by Academia-Industry collaborating All-Japan system:
-
Newly Synthesized Fungal Compound Can Switch on a Self-destruct Button for Cancer
6/12/2020
Cancers cells use a special technique to propagate; they delete their “programmed death” gene through mutation, “forget” to die when their lifetime is over, and continue to grow instead
-
Shionogi Accelerates Development of Potential COVID-19 Treatments and Vaccine
4/28/2020
In response to the novel coronavirus (SARS-CoV-2), Shionogi & Co., Ltd. (hereafter “Shionogi”), a pharmaceutical company with a major focus on infectious diseases, has joined the ranks of pharmaceutical companies across the globe and is working with public institutions, academia and partner companies in the following efforts to fight against COVID-19: Commitment to the discovery of novel
-
Masking the Memory of Fear: Treating Anxiety Disorders such as PTSD with an Opioid
2/19/2020
In a breakthrough study, scientists from Japan find the potential of an opioid drug to help numb fear memory
-
Bone Abnormalities in Systemic Autoimmune Disease
4/26/2019
An article published in Experimental Biology and Medicine details abnormalities in bone pathology that occur in systemic autoimmune disease.
-
Hitachi's Heavy Ion Beam Therapy System Starts Treatment at Osaka Heavy Ion Therapy Center
10/16/2018
Hitachi, Ltd. announced today that its heavy ion beam therapy system(1) has started treatment at Osaka Heavy Ion Therapy Center as of October 16. This marks the first operation of Hitachi's first heavy ion therapy system.
-
QView Medical Inc. Announces FDA PMA Approval for QVCAD for the GE Invenia™ 3D Automated Breast Ultrasound System (“ABUS”)
12/22/2017
QView Medical is pleased to announce FDA approval for QVCAD to be used with the GE Invenia™ ABUS in breast screening for asymptomatic dense breasted women whose mammogram was negative.
-
Volpara Receives Regulatory Clearances in Japan and Taiwan
11/20/2017
In Japan, the full Volpara Enterprise suite of products has received regulatory approval as a Class II medical device.
-
OSE Immunotherapeutics Publishes New Data on FR104, CD28-Antagonist Immunotherapy
10/19/2017
FR104 shows immune tolerance superiority over CTLA4-Ig in humanized skin transplant model.